

Don't face the journey with lymphoma alone.

The journey with non-Hodgkin lymphoma (NHL) shouldn't be a lonely one—join a growing community of people seeking answers through clinical research. Consider participating in the EPCORE NHL-5 clinical research study.

The EPCORE NHL-5 Clinical Research Study

The EPCORE NHL-5 Study is evaluating the safety and tolerability of an investigational drug in combination with other drugs for adults with NHL.

You may be able to take part in the EPCORE NHL-5 Study if you:

- o Are at least 18 years old
- Have a diagnosis of diffuse large B-cell lymphoma (DLBCL), including:
 - Treatment-naïve DLBCL
 - Treatment-naïve: You have not had any cancer treatments
 - Relapsed or refractory DLBCL
 - Relapsed: Your lymphoma previously responded to therapy but progressed 6 months or later after completing therapy
 - Refractory: Your lymphoma either progressed during therapy, did not respond to prior therapy, or progressed within 6 months after completing therapy (including maintenance therapy)

If you are interested in participating, the study doctor and staff will review additional eligibility criteria with you.

FAQs

What's involved with participation in the EPCORE NHL-5 Study?

Participants in this study will be given an investigational drug that will be delivered by subcutaneous injection (under the skin). Participants will be assigned to a study treatment group depending on the type of lymphoma they have. During the study, the investigational drug will be taken in combination with other drugs for adults with NHL. There is no placebo in this study, which means all participants will receive study treatment.

This study is divided into the following parts:

- Screening
 - Approximately 28 days, which is usually completed in 1 study visit, but can sometimes be more than 1 visit
 - Determines if you can be in the study
- Study Treatment Period
 - · Length of time on study treatment varies based on the response to the study drug
 - The study drug is given in 28-day or 21-day cycles, depending on your assigned study treatment group
- Post-Study Treatment Follow-Up
 - Participants will have a follow-up visit within about 120 days of their last study treatment, and then additional follow-up about every 12 weeks after the last study visit until the study ends

Total study duration will depend on each participant's response to the study drug. Participants may leave the study at any time without further explanation.

Does participating in this study cost anything?

If you qualify for and agree to participate in the study, you will not have to pay for the investigational drug. In addition, reimbursement for study-related travel expenses may be available.

If prequalified, what can I expect on my first visit to the study clinic?

This initial appointment is an opportunity for you to:

- Ask any important questions you may have. These can be any questions you may have about this study or clinical research in general.
- O Determine if the EPCORE NHL-5 Study may be right for you. You will speak with a study coordinator and learn more about the study. The study coordinator will ask you about your health history to determine if you are eligible for the study. If you are eligible, you will be given the opportunity to decide if participation is right for you. If you agree to take part, you will be asked to review and sign a consent form for study participation. You can also leave the study at any time. Once you have signed the study consent form, the research staff will perform a series of tests to determine if you are right for the study, and if the study is right for you.



What if my condition worsens or I have side effects?

You should make sure to inform your study doctor of any new symptoms you experience while participating in the study. If you experience a worsening of your disease at any time during the study, please let the study doctor and staff know.

Where are the study clinics located?

There are study clinics located throughout the world. Find a location near you at: **EPCORE-trials.com/locations**.